Pneumocystis jiroveci prophylaxis in patients undergoing Bendamustine treatment: the need for a standardized protocol

被引：9

作者：

Abkur, Tarig Mohammed ^{[1
]}

Saeed, Mamoun ^{[1
]}

Ahmed, Saad Zeinalabdin ^{[1
]}

McArthur, Ryan ^{[2
]}

Leahy, Maeve ^{[1
,2
]}

O'Leary, Hilary ^{[1
,2
]}

O'Keeffe, Denis ^{[1
,2
]}

机构：

[1] Univ Hosp Limerick, Dept Haematol, St Nessan Rd, Limerick, Ireland

[2] Univ Limerick, Grad Entry Med Sch, Limerick, Ireland

来源：

CLINICAL CASE REPORTS | 2015年 / 3卷 / 04期

关键词：

Bendamustine; Pneumocystis; Trimethoprim/Sulfamethoxazole;

D O I：

10.1002/ccr3.195

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The decision for PJP prophylaxis depends on a physician's evaluation of multiple variables. The high rate of PJP infection described in this article combined with the known impaired T-cell function post Bendamustine treatment justifies considering all patients for PJP prophylaxis when they receive Bendamustine treatment.

引用

页码：255 / 259

页数：5

共 24 条

[1]

[Anonymous], 2010, NHSG AC SECT EMP ANT

[2]

BAUGHMAN RP, 1994, PNEUMOCYSTIS CARINII, P381

[3] Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis? [J].

Besada, Emilio ;

Nossent, Johannes C. .

CLINICAL RHEUMATOLOGY, 2013, 32 (11) :1677-1681

[4] Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients [J].

Bollee, Guillaume ;

Sarfati, Claudine ;

Thiery, Guillaume ;

Bergeron, Anne ;

de Miranda, Sandra ;

Menotti, Jean ;

de Castro, Nathalie ;

Tazi, Abdellatif ;

Schlemmer, Benoit ;

Azoulay, Elie .

CHEST, 2007, 132 (04) :1305-1310

[5] Bendamustine in Indolent Non-Hodgkin's Lymphoma: A Practice Guide for Patient Management [J].

Brugger, Wolfram ;

Ghielmini, Michele .

ONCOLOGIST, 2013, 18 (08) :954-964

[6] Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma [J].

Carter, Stephanie J. ;

Bernstein, Steven H. ;

Friedberg, Jonathan W. ;

Barr, Paul M. .

LEUKEMIA RESEARCH, 2011, 35 (11) :E223-E224

[7] Bendamustine Produces Durable Responses With an Acceptable Safety Profile in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma [J].

Cheson, Bruce D. ;

Friedberg, Jonathan W. ;

Kahl, Brad S. ;

Van der Jagt, Richard H. ;

Tremmel, Lothar .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (06) :452-457

[8]

Curtis JR, 2000, AM J RESP CRIT CARE, V162, P393, DOI 10.1164/ajrccm.162.2.9909014

[9] Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group [J].

Fischer, Kirsten ;

Cramer, Paula ;

Busch, Raymonde ;

Boettcher, Sebastian ;

Bahlo, Jasmin ;

Schubert, Joeerg ;

Pflueger, Karl H. ;

Schott, Silke ;

Goede, Valentin ;

Isfort, Susanne ;

von Tresckow, Julia ;

Fink, Anna-Maria ;

Buehler, Andreas ;

Winkler, Dirk ;

Kreuzer, Karl-Anton ;

Staib, Peter ;

Ritgen, Matthias ;

Kneba, Michael ;

Doehner, Hartmut ;

Eichhorst, Barbara F. ;

Hallek, Michael ;

Stilgenbauer, Stephan ;

Wendtner, Clemens-Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (26) :3209-3216

[10]

FREEDBERG KA, 1991, J ACQ IMMUN DEF SYND, V4, P521

← 1 2 3 →